Indications

E-Learning: Waldenström’s Macroglobulinemia (WM)

Oncology · Hematology Duration: 1h minutes

Introduction to WM

You have already completed: 0%

0%

Use this link to come back to your current progress in the future:

Waldenström’s Macroglobulinemia (WM)
Introduction to WM
Incidence and prevalence
Causes and risk factors
Symptoms and diagnosis
Staging risk assessment
Treatment Landscape of WM
Current treatment guidelines for WM
First-line therapy
- Chemoimmunotherapy
- Bruton’s tyrosine kinase (BTK) inhibitors
- Other treatment options for WM
- Assessment of response to primary therapy
- Follow-up after primary treatment
- Treatment of IgM-related peripheral neuropathy
Maintenance therapy
Treatment options for previously treated/relapsed WM
- Ibrutinib for previously treated patients with WM
- Real-world evidence: ibrutinib monotherapy outside of a clinical trial setting in WM
- Other treatment options for relapsed MW
Future Perspectives
Summary/Take Home Messages